This is the largest change to my consultation list in years, and it arrived from outside the field entirely.
Rapid weight loss on GLP-1 medication produces a recognisable pattern: volume loss in the temples and midface, a hollowing under the eye, loosening of the skin envelope, and jowling that looks a decade premature. The popular name for it is unhelpful but the phenomenon is real. Surveys of facial plastic surgeons report a marked rise in patients presenting with weight-loss-related facial change, and public search interest in the term has risen by orders of magnitude.
What interests me clinically is that this is not simply ageing accelerated. Facial fat is lost in a particular distribution and at a pace that gives the skin no time to remodel. A patient who loses the same weight over three years looks different from one who loses it over nine months, and the difference is not subtle.
Timing matters more than technique
The most common error I see is intervening while weight is still moving. A face treated at the midpoint of a significant weight loss will need retreating, and volume placed into a structure that is still changing does not stay where you put it. My advice is nearly always to wait for a stable weight, and it is nearly always unwelcome.
Filler is frequently the wrong answer
The instinct, on seeing volume loss, is to replace volume. But a large part of what these patients present with is a skin envelope that no longer fits its contents. Adding volume to lax skin produces a heavy, filled appearance rather than a restored one, and at the doses required to make a visible difference the result usually looks treated.
Where the dominant problem is laxity rather than deflation, the honest answer is surgical, and saying so costs a practice money.
A population new to all of this
A substantial proportion of these patients have never had a cosmetic treatment and had never intended to. They are not arriving with a shopping list. They are arriving distressed by a change they didn't anticipate and weren't warned about, which makes them unusually vulnerable to being sold a great deal at once.
The part nobody wants to say
These medications are, for many people, doing something genuinely valuable for their health. A facial consequence is not a reason to stop, and I have had patients come in asking whether they should. That question belongs to the doctor prescribing it. My job is to make the aesthetic consequence manageable rather than to make it a reason for abandoning treatment.
The evidence base here is young. The reviews published this year call for prospective studies and there is no GLP-1-specific protocol worth the name yet. What exists is the ordinary toolkit applied with more than ordinary attention to timing. Anyone offering you a proprietary programme for this has got ahead of the data.